Below are some of the month's news highlights for people with PV, ET and MF. As always we mention a few research opportunities for your consideration.

In case you haven't read it lately, the mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for the blood cancers polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN). To that end, we will soon issue a request for proposals for new MPN research to fund in 2017. Please keep an eye out for our announcement, and be sure to share it with your physician or hospital. 


Michelle Woehrle
Executive Director
New Yorker article discusses CRISPR and data sharing 
MPNRF has funded a few CRISPR gene editing studies.

myMPN is now beta testing! 
Our own patient registry - myMPN - is being tested by patient volunteers right now. 
Patient Power talks to Dr. Mascerenhas about Pacritinib
The drug was recently taken off hold by the FDA and is now in a new trial.
Participate in research! 
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

A lead-in cohort of ~20 patients with primary or secondary myelofibrosis previously treated with 1 or more Janus kinase inhibitors enrolled to single-agent glasdegib to evaluate safety and tolerability. Learn more.

Essential Thrombocythemia Study 

Quintiles is conducting a study sponsored by Incyte to learn which symptoms of ET are the most common, and how these symptoms typically affect the lives of patients who live with the disease. 
Learn more.

Research Tissue Bank for people with MPN 

This study allows for the preservation and/or storage of a small portion one or more of the following tissues: 
Peripheral blood;  Bone marrow;  Bone marrow biopsy;  A phlebotomized unit of blood;  Spleen cells;  Toenail clippings. The goals of this research study are to understand the causes of MPDs. Learn more.